Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 9/20 | 0.51 |
| ▸ | HTR2A | P28223 | 8/20 | 0.51 |
| ▸ | HTR1A | P08908 | 6/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078388 | 0.89 | KDM4E (0.56) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL1208104 | 0.87 | EGLN1 (0.62) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL16307678 | 0.85 | HDAC3 (0.57) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL213288 | 0.83 | EGLN1 (0.60) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL31016920 | 0.83 | HDAC3 (0.65) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL5926434 | 0.81 | EGLN1 (0.67) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL15204136 | 0.81 | EGLN1 (0.52) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL5100085 | 0.81 | EGLN1 (0.52) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL14876092 | 0.81 | EGLN1 (0.57) | EGLN1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL14067741 | 0.80 | MEN1 (0.53) | EGLN1HDAC3HDAC1HDAC2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | F. HOFFMAN-LA ROCHE LTD | 2016-12-29 | — | — | US | disclosed |
| CN-103958521-B | Pyrimidin-4-one derivatives and their use in the treatment, alleviation or prevention of viral diseases | 弗·哈夫曼-拉罗切有限公司 | 2016-10-19 | — | — | CN | disclosed |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2016-10-13 | — | — | US | disclosed |
| EP-2794616-B1 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | TPMT, TYMP, HPRT1 | EGLN1 3864/4885EGFR 4818/4885HDAC3 2822/4885 |
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | TTR, TYMP, TPMT | EGLN1 4110/4885EGFR 4632/4885HDAC3 3180/4885 |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | ALAD, CYP27A1, FAH | EGLN1 1937/4885EGFR 3904/4885HDAC3 146/4885 |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | FAH, SLC10A1, OAT | EGLN1 1655/4885EGFR 4252/4885HDAC3 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.